Activation pattern within Koch's triangle during sinus rhythm in patients with and without atrioventricular nodal reentrant tachycardia.

BACKGROUND: Several studies have visualized the slow pathway during sinus rhythm using high-density mapping of Koch's triangle (KT) in patients with atrioventricular nodal reentrant tachycardia (AVNRT). However, it is unclear whether the slow pathway can be visualized in all people. Therefore, we evaluated the activation pattern within KT during sinus rhythm in patients with and without AVNRT. METHODS: High-density mapping using the Advisor HD Grid mapping catheter (Abbott) within KT during sinus rhythm was created in 10 patients with slow-fast AVNRT and 30 patients without AVNRT. RESULTS: In 8 (80%) patients with AVNRT, the activation pattern pivoting around a block line (BL) within KT was observed. In 12 (40%) patients without AVNRT, similar activation pattern pivoting around BL was observed, but jump was observed in 11 (92%) of these patients. In all patients, the activation pattern pivoting around BL was observed in 17 (85%) of 20 patients with jump, but only 3 (15%) of 20 patients without jump (p < 0.0001). During jump, there was a long period of no potential from the last atrial potential within KT to the His bundle potential, suggesting the slow pathway conduction through the rightward inferior extension that cannot be visualized. A linear ablation between the pivot point and the septal tricuspid annulus was successful for slow-fast AVNRT. CONCLUSION: Although the slow pathway could not be visualized using high-density mapping during sinus rhythm, the activation pattern pivoting around BL within KT was observed in most patients with the dual pathway physiology, with or without AVNRT.

High-power, short-duration ablation during Box isolation for atrial fibrillation.

BACKGROUND: It has been demonstrated that a high-power, short-duration (HPSD) ablation during pulmonary vein (PV) isolation is effective and safe. However, studies about the HPSD ablation during the posterior wall isolation, the Box isolation (BOXI), are limited. We evaluated the efficacy, feasibility, and safety of HPSD ablation during BOXI. METHODS: One-hundred sixty patients with all types of atrial fibrillation underwent BOXI with HPSD ablation (n = 80) or conventional technique (n = 80). In the HPSD group, ablation was performed with 50 W and a target lesion size index of 5.0 using a contact force (CF) sensing catheter. Ablation near the esophagus was performed with 50 W for 5 seconds and a CF < 10 g. In the conventional group, ablation was performed with 30-40 W for 30 seconds, but 20 W near the esophagus. RESULTS: The BOXI creation (26 ± 8 minutes vs 47 ± 17 minutes, P < .0001) and procedure (65 ± 12 minutes vs 87 ± 23 minutes, P < .0001) times were significantly shorter in the HPSD group than the conventional group. The number of pacing capture sites did not differ between the two groups. No complications including gastrointestinal symptoms occurred. The atrial tachyarrhythmia-free rate at 12-months after a single procedure was 86.3% in the HPSD group and 76.3% in the conventional group, respectively (P = .132). The incidence of PV reconnections and gaps in the lines during the second procedure did not differ between the two groups. CONCLUSION: The BOXI with HPSD ablation is effective, feasible, and safe with short BOXI creation and procedure times without reducing the clinical outcomes.

Impact of Box Isolation on Rotors and Multiple Wavelets in Persistent Atrial Fibrillation.

BACKGROUND: Additional benefits of posterior left atrial (LA) box isolation (BOXI) over pulmonary vein isolation (PVI) in persistent atrial fibrillation (perAF) have been reported, but the mechanism is still unclear. We evaluated the effects of BOXI on rotors and multiple wavelets in the whole LA.Methods and Results:Twenty patients with perAF (including 12 cases of longstanding perAF) underwent PVI. Real-time phase mapping (ExTRa Mapping) was performed in the whole LA during AF. Subsequently, BOXI was added and re-ExTRa Mapping was performed again at the same site. The nonpassively activated ratio (%NP), the ratio of the form of rotors and multiple wavelets to the recording time, was compared before and after BOXI. After BOXI, the %NP significantly decreased in the anterior wall (from 53±22% to 39±23%, P=0.010), inferior wall (from 51±16% to 34±19%, P=0.001), and LA appendage (from 23±27% to 16±19%, P=0.049). However, there were no significant differences in the septum (49±19% vs. 49±18%, P=0.562) or lateral wall (41±19% vs. 38±15%, P=0.526). CONCLUSIONS: BOXI not only reduced the critical mass for maintenance of AF, but also decreased the rotors and multiple wavelets in the anterior wall, inferior wall and LA appendage during perAF.

Effects of additional ablation of low-voltage areas after Box isolation for persistent atrial fibrillation.

BACKGROUND: Previous studies reported that ablation of low-voltage areas (LVAs) after pulmonary vein isolation (PVI) improves the success rate in persistent atrial fibrillation (PerAF) patients with LVAs. However, the need for LVA ablation in addition to the posterior left atrial isolation, Box isolation (BOXI), for PerAF is unclear. We evaluated the effects of LVA ablation after BOXI for PerAF with LVAs. METHODS: In 115 patients with PerAF (75 longstanding PerAF), LA voltage maps were created during sinus rhythm after PVI. Subsequently, BOXI was performed. In 61 patients without LVAs (<0.5 mV), BOXI alone was performed. Fifty-four patients with LVAs were randomly assigned to BOXI plus LVA ablation (33 patients) or BOXI alone (21 patients). RESULTS: The rate of AF termination or cardioversion after BOXI was significantly higher than that after PVI (100% vs 88%, P < 0.001). The inducibility of atrial tachyarrhythmia after BOXI was significantly lower than that after PVI (27% vs 100%, P < 0.001). During 24 ± 9 months of follow-up after a single procedure, atrial tachyarrhythmia-free rate in the patients with LVAs, was significantly lower than that without LVAs (65% vs 82%, P = 0.043). However, the success rate was not significantly different between the BOXI plus LVA ablation group and the BOXI alone group of patients with LVAs (67% vs 62%, P = 0.722). CONCLUSION: BOXI facilitates AF termination and its non-inducibility. Among patients with PerAF, BOXI alone may be adequate in cases without LVAs. Although cases with LVAs have higher risk of AF recurrence, additional LVA ablation does not improve the outcomes much.

Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation.

BACKGROUND: Additional ablation of complex fractionated atrial electrograms (CFAE) after pulmonary vein isolation (PVI) has been shown to improve the success of ablation of persistent atrial fibrillation (AF). However, extensive ablation is often necessary to eliminate all CFAE or to terminate AF. We assessed the usefulness of the administration of an antiarrhythmic drug (AAD) before CFAE ablation. METHODS AND RESULTS: One-hundred and ten patients with persistent AF first underwent PVI, roof and floor linear ablation (box isolation). One hundred patients who remained in AF after box isolation were then randomized to either receive (AAD group, n=50) or not receive (no-AAD group, n=50) intravenous nifekalant (0.3mg/kg) followed by a CFAE ablation. In the AAD group, nifekalant terminated AF in 19 (38%) patients and ablation of localized CFAE was performed in 31 patients who remained in AF after nifekalant, and terminated AF in 11 (35%) patients. In the no-AAD group, ablation of CFAE terminated AF in 13 (26%) patients. The AAD group had a significantly lesser number of radio frequency applications at CFAE sites (18 ± 12 versus 36 ± 10, p<0.0001) and shorter procedure time (162 ± 34 versus 197 ± 29 min, p<0.0001) compared with the no-AAD group. However, there was no significant difference in success rate at 12 months after a single ablation procedure between the two groups (AAD group, 74% versus no-AAD group, 76%). CONCLUSIONS: An approach to ablation using nifekalant may be useful in localizing areas of CFAE, reducing the number of applications at CFAE sites and procedure time. Ablation of only CFAE localized with nifekalant may be sufficient for clinical outcome.